Background
Maja Buszko
Edited by: Amy Rosenberg, EpiVax, United StatesReviewed by: Maja Buszko, Janssen Research and Development, LLC, United States; Joanna Hester, University of Oxford, United Kingdom†These authors share first authorship‡These authors share senior authorshipThe administration of modified immune cells (MIC) before kidney transplantation led to specific immunosuppression against the allogeneic donor and a significant increase in regulatory B lymphocytes. We wondered how this approach affected the continued clinical course of these patients.